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Background. Albuminuria is an important predictor of risk of
progressive renal disease, cardiovascular disease, and mortality;
however, the prevalence in the general population is not well
defined. We determined estimates of the population prevalence
and associations of microalbuminuria and macroalbuminuria in
Australian adults; 11,247 Australians aged ≥25 years living in 42
randomly selected population clusters were tested for albumin-
uria (spot urine albumin:creatinine (mg/mmol): normal <3.4,
microalbuminuria 3.4 to 34, macroalbuminuria >34).
Methods. Prevalence of micro- and macroalbuminuria were
assessed with age, sex, obesity, smoking, hypertension (≥140/90
mm Hg or known diagnosis on treatment), glucose metabolism
status (WHO criteria according to fasting glucose and oral glu-
cose tolerance test), ischemic heart and cerebrovascular disease,
and low glomerular filtration rate (calculated glomerular filtra-
tion rate <60 mL/min/1.73m2).
Results. Microalbuminuria and macroalbuminuria protein-
uria were present in 6.0% and 0.6% of the population, respec-
tively. The majority of subjects with microalbuminuria (64%)
and macroalbuminuria (76%) had hypertension, and approx-
imately half of those with albuminuria had abnormal glucose
metabolism. Of all participants with microalbuminuria, 25.9%
had normal blood pressure and glucose metabolism, and in this
group, alternative associations of microalbuminuria included
obesity (13.5%), smoking (20.7%), and low glomerular filtra-
tion rate (12.3%).
Conclusion. Albuminuria is present in a small percentage of
the general adult population, but is highly prevalent in subjects
with hypertension and/or abnormal glucose metabolism. The
majority of cases of microalbuminuria and macroalbuminuria
in the general population are among those with hypertension.
In the general population, microalbuminuria has been
associated with increased risk of cardiovascular disease
and premature death [1–2]. For patients with renal dis-
ease or diabetes mellitus, the presence of albuminuria
is associated with an increased risk of progressive renal
impairment, cardiovascular disease, and overall mortal-
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ity [3–5]. The prevalence of albuminuria may, therefore,
have major implications for potential screening and in-
tervention programs, as well as health outcomes.
We therefore sought to determine the population
prevalence of microalbuminuria and macroalbuminuria
and to examine the effects of age, sex, glucose metabolism
status determined by fasting blood glucose and oral glu-
cose tolerance test, blood pressure, and glomerular filtra-
tion rate on prevalence.
METHODS
The Australian Diabetes, Obesity and Lifestyle Study
was a nation-wide, population-based survey, undertaken
between May 1999 and December 2000, to determine the
prevalence of diabetes mellitus, obesity, and cardiovas-
cular disease risk factors. Indicators of kidney disease
and assessment of kidney function was also assessed.
The details of the survey have been published elsewhere
[6]. Written informed consent was obtained from all
individuals.
Of the 11,247 subjects who completed the survey, data
were available for urine albumin to creatinine ratio in
10,606 (94.3%). Information on variables used in this
analysis was collected during the initial household in-
terview. This was followed by a physical examination
that included anthropometry, blood pressure measure-
ments, collection of a fasting blood specimen and a spot
morning urine specimen, and a standard 75 g oral glu-
cose tolerance test. Albuminuria was defined in terms
of urine albumin to creatinine ratio. Microalbuminuria
was defined as a urine albumin to creatinine ratio 3.4
to 34 mg/mmol, and macroalbuminuria as a ratio of
34 mg/mmol or greater [7]. Glomerular filtration rate was
calculated using the Cockcroft-Gault formula and adjust-
ment for body surface area. All analyses were conducted
using Stata version 8.2 (Stata Corporation, College Sta-
tion, TX, USA) survey commands for analyzing complex
survey data. The distribution of microalbuminuria and
macroalbuminuria and identification of subgroups with
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Table 1. Clinical characteristics of individuals with or without
albuminuria
No Micro- Macro-
albuminuria albuminuria albuminuria
Totala % 93.4 (0.6) 6.0 (0.6) 0.7 (0.1)
Male sex% 50.2 (0.6) 42.7 (2.1) 52.4 (14.3)
Agea years 47.4 (0.7) 60.8 (1.7) 61.0 (2.6)
Obesitya % 20.4 (1.1) 28.1 (2.9) 44.2 (11.0)
Current smokinga % 16.2 (1.8) 14.8 (1.5) 26.0 (14.4)
Hypertensiona %
Normal blood pressure 73.2 (1.6) 36.5 (3.8) 21.5 (8.6)
Untreated 15.0 (0.9) 24.4 (1.9) 34.5 (13.3)
Treated 11.7 (0.9) 39.1(3.7) 44.0 (10.5)
Glucose metabolisma %
Normal 78.0 (1.1) 47.4 (3.3) 57.4 (11.4)
Impaired fasting glucose 5.7 (0.4) 7.3 (2.4) 3.6 (3.4)
Impaired glucose tolerance 10.1 (0.5) 20.0 (2.6) 7.7 (5.5)
Diabetes mellitus 6.2 (0.6) 25.5 (3.0) 31.3 (9.2)
Hypercholesterolemiaa 65.7 (1.4) 75.6 (1.8) 82.3 (6.7)
Ischemic heart diseasea 5.3 (0.4) 19.2 (3.1) 15.9 (3.9)
Cerebrovascular diseasea 2.0 (0.3) 5.6 (1.0) 11.6 (4.4)
GFR <60 mL/min/1.73m2a% 9.5 (1.0) 37.8 (4.5) 36.3 (7.9)
GFR, glomerular filtration rate. Data are mean or percent prevalence
(standard error).
aP < 0.001 for a difference between the three groups. Obesity defined as body
mass index ≥30 kg/m2.
high prevalence of these urinary abnormalities was de-
termined by cross-tabulation covariates with microalbu-
minuria and macroalbuminuria.
RESULTS
Table 1 outlines the clinical characteristics of indi-
viduals with or without albuminuria. Overall, 6.0% of
subjects had microalbuminuria, and 0.7% had macroal-
buminuria. Significant differences in the prevalence of
albuminuria were present according to obesity, hyperten-
sion (treated and untreated), glucose metabolism, hyper-
cholesterolemia, ischemic heart disease, cerebrovascular
disease, and impaired glomerular filtration rate.
Of the 6.0% of the population with microalbumin-
uria, the majority had hypertension, abnormal glucose
metabolism, or both. Sixty-three percent of microalbu-
minuria was found in subjects with hypertension: 21.6%
in those with hypertension alone, and 41.4% in those with
hypertension and abnormal glucose metabolism; 52.5%
of microalbuminuria was found in those with abnormal
glucose metabolism: 26.1% in those with diabetes melli-
tus, 19.6% in those with impaired glucose tolerance, and
6.8% in those with impaired fasting glucose. In the partic-
ipants with known diabetes mellitus, micro- and macroal-
buminuria was present in 24.9% and 4.6%, respectively,
whereas in those in whom diabetes mellitus was newly
diagnosed as a result of the survey, 15.9% and 1.3% had
micro- and macroalbuminuria, respectively. Of all partic-
ipants with microalbuminuria, 25.9% had normal blood
pressure and glucose metabolism, and in this group, alter-
native associations of microalbuminuria included obesity
in 13.5%, current smoking in 20.7%, and low glomerular
filtration rate in 12.3%. Of those with macroalbuminuria,
78% were hypertensive, and 43% had abnormal glucose
metabolism.
DISCUSSION
This study confirms and extends previous findings
documenting the prevalence of albuminuria in a large
population-based cohort. The majority of cases of al-
buminuria were found within identifiable subgroups of
the cohort. Two thirds of microalbuminuria was found
in association with hypertension. Half of all cases of mi-
croalbuminuria were seen in subjects with abnormal glu-
cose metabolism, and a similar percentage of all cases
were found in subjects over 65 years of age. This infor-
mation has implications at several levels of health care.
From the general practitioner’s perspective, the patients
found to have albuminuria at an annual check-up have
a 60% probability of having hypertension. In addition,
the patient has a 50% probability of having abnormal
glucose metabolism, and testing for this should be con-
sidered. From a therapeutic perspective, drugs that target
the renin-angiotensin pathway are known to be effective
in improving renal and cardiovascular outcomes for pa-
tients with albuminuria in the setting of hypertension or
abnormal glucose metabolism [8–12]—the subgroups of
the population in which over 75% of cases of albumin-
uria reside. At a population level, screening all hyperten-
sive individuals in the general population would identify
63.7% of cases of microalbuminuria.
The AusDiab data carry significant messages about dis-
ease awareness and therapy in the community. For every
subject known to have diabetes mellitus, another with
previously undiagnosed diabetes mellitus was detected
by fasting plasma glucose or oral glucose tolerance test-
ing [13]. For every subject on treatment for hypertension,
another was found with either undiagnosed or untreated
hypertension. Thus, in the Australian community, at least,
significant underdetection and consequent undertreat-
ment of diabetes mellitus, hypertension, and proteinuria
are prevalent. This situation is unlikely to be different in
other communities. Appropriate identification and treat-
ment of such individuals may have a dramatic impact on
population trends in the burden of renal and cardiovas-
cular disease.
CONCLUSION
Microalbuminuria is present in a small percentage
of the general population, but is highly prevalent
among those with hypertension and abnormal glucose
metabolism.
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